Gal-3 is associated with inflammatory diseases such as systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis, and Gal-3 inhibition is associated with neuropathic pain attenuation [27,28,29,30]. Here, LGALS3 is linked to systemic sclerosis.